Loading lessons…
Loading lessons…
Curated lessons across 8 learning paths — from first concepts to trial summaries and practical protocols. Pick your level, follow the curriculum, and build real understanding.
Where are you starting?
Choose a learning path below or search the library. Progress saves in your browser.
Prefer timeline chaos? Peptide X Quiz · Literacy certify
Pick a track — progress rings update as you complete lessons.
28 lessons
16mGlutathione is a small antioxidant your cells already make. That biological role does not automatically make every supplement or IV drip effective. Here is what it is, how it works, and what human studies actually show, including the limits and risks.
9mNAD+ is essential to cells. That does not make every NAD+ treatment effective. A practical guide to IV claims, oral precursors and what human studies actually measured.
7mPatients ask about BPC-157 after extractions and implants. The dental literature is one rat periodontitis model, one rat oral-injury model, and three uncontrolled human cases. Here is each one.
12mThe only peptides with large controlled trials for weight loss are the GLP-1 class: semaglutide, tirzepatide, and the oral options approved in 2025 and 2026. Retatrutide is next but still investigational. Here's how they work, what the trials showed, and how to access them through a licensed clinician.
8mFoundayo is the brand name for orforglipron — a once-daily oral small-molecule GLP-1 approved in April 2026. Here's what the pill is, how it differs from injectables, and what trials studied — not a dosing prescription.
7mTwo of Lilly's next obesity drugs work in completely different ways. Here's how eloralintide (amylin) and retatrutide (triple agonist) compare on the published data.
7mThe first small-molecule oral GLP-1 option removes injection training and cold-chain handling, but daily dosing creates a different adherence job.
8mThe loudest peptide stories are moving at different speeds. PCAC recommendations await FDA action, oral GLP-1 access is real, and the next obesity programs still have filing or review milestones ahead.
8m5-Amino-1MQ dosage searches grew more than 1,400 percent. The stack page already ranks. This companion stays on milligram ranges and oral versus subQ handling language.
11mEloralintide is Eli Lilly's once-weekly selective amylin receptor agonist. It produced up to 20.1% average weight loss at 48 weeks in Phase 2, and up to 23.3% when paired with tirzepatide. It is not approved anywhere, and its Phase 3 program will not read out before 2028.
8mAmycretin puts GLP-1 and amylin in one molecule — with both a pill and a weekly shot in development. Here's the beginner map before Phase 3 ladders finalize.
9mAmycretin is Novo's dual GLP-1 + amylin molecule with both oral and injectable programs. Here's the early dosing map and why Phase 3 is the next SEO wave.
8mCagrilintide is the amylin half of CagriSema. Here's the dosing map people actually search — 2.4 mg weekly combo context, monotherapy signal, and how not to cross-titrate with eloralintide.
8mSearching for eloralintide dosage? Here is the clean map of Phase 2 once-weekly doses, titration arms, and weight-loss results — framed as clinical education, not a DIY protocol.
8mAmylin + incretin is the stacking thesis behind CagriSema — and now eloralintide. Here's the clinical logic for combining pathways, without turning investigational drugs into DIY stacks.
8mPeople searching how to reconstitute eloralintide usually want a retatrutide-style BAC water chart. Here's the honest version — clinical weekly product vs unverified research powder.
7mAmylin agonists can feel GLP-1-like in the gut. Here's how to think about eloralintide tolerability, escalation, and symptom tracking without turning trial data into fear content.
7mWeekly amylin agonists are not MOTS-c. Here's when to inject eloralintide for tolerability — dose-day meals, evening vs morning, and what to log.
8mBoth hit amylin biology. One is Lilly's Phase 3 monotherapy / combo candidate. The other is the amylin half of CagriSema. Here's a clear comparison for people following the next wave of obesity peptides.
8mTwo weekly amylin programs, two sponsors, two data shapes. Here's a clear eloralintide vs petrelintide comparison for people following the next obesity wave.
8mPhase 2 put eloralintide on the board with roughly 9–20% mean weight loss at 48 weeks. Here's the results breakdown — and the troubleshooting mindset for plateaus on any amylin or GLP-1 protocol.
6mMacupatide is the Lilly code name beside eloralintide that most people skip. This beginner guide explains what it is — and what not to invent about dosing yet.
7mEloralintide is only half the Lilly amylin headline. Macupatide shows up in the same ClinicalTrials.gov cluster. Here's the combo literacy guide.
8mOrforglipron is Lilly's once-daily oral small-molecule GLP-1. Here's the titration ladder searchers want — 1 mg start, step-ups every four weeks, and Phase 3 maintenance doses.
7mPetrelintide is the amylin analog drawing attention for tolerability. This beginner guide covers what it is, what ZUPREME-1 showed, and what to watch next.
8mThe next metabolic peptide wave is not just stronger GLP-1 dosing. Amylin, GIP, glucagon, and combination protocols are changing what serious tracking should include.
9mFor years, GLP-1 therapy meant a weekly injection. The FDA just changed that. Foundayo is the first oral GLP-1 approved for weight management, and the implications for the peptide community go far beyond convenience.
10m5-Amino-1MQ blocks NNMT instead of suppressing appetite. This guide covers oral dosing ranges and why people stack it with GLP-1s and MOTS-C for stubborn visceral fat.
Also available at /blog for legacy links.